Price
CHART BY
Frequently asked questions
What is Terns Pharma's market capitalization?
The market capitalization of Terns Pharma is $3.95B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Terns Pharma?
Terns Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.032. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Terns Pharma's stock?
Currently, 10 analysts cover Terns Pharma's stock, with a consensus target price of $54.22. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Terns Pharma?
Terns Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$107.87M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Terns Pharma?
Terns Pharma has a free cash flow of -$77.99M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Terns Pharma have, and what sector and industry does it belong to?
Terns Pharma employs approximately 59 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Terns Pharma's shares?
The free float of Terns Pharma is 92.36M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.95B
- EPS (TTM)
- -$1.032
- Free Float
- 92.36M
- EBITDA (TTM)
- -$107.87M
- Free Cashflow (TTM)
- -$77.99M
Pricing
- 1D span
- $36.43$38.97
- 52W span
- $1.865$48.26
Analyst Ratings
The price target is $54.22 and the stock is covered by 10 analysts.
Buy
10
Hold
0
Sell
0
Information
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
- Employees
- 59
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- TERN
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet